Conduction System Pacing With AV Node Ablation Versus Pulmonary Vein Isolation Authors: Nikola Kozhuharov, Haran Burri Published: 2026 ABSTRACT Corresponding AuthorKey Words: atrial fibrillation, atrioventricular node ablation, conduction system pacing, heart failure, pulmonary vein isolation, ventricular rate regularization Persistent atrial fibrillation (AF) and heart failure (HF) frequently coexist and are associated with a particularly poor prognosis.1,2 AF contributes to HF progression through loss of atrial contraction, persistent tachycardia, and the hemodynamic consequences of an irregular ventricular rhythm, which impair cardiac output and promote adverse remodeling. Conversely, elevated filling pressures and atrial stretch favor AF persistence and reduce the likelihood of maintaining sinus rhythm.1,3 Contemporary interventional management therefore follows 2 fundamentally different approaches: 1) catheter ablation to achieve pulmonary vein isolation (PVI), which aims to restore sinus rhythm; or 2) atrioventricular node ablation (AVNA) combined with permanent pacing (pace-and-ablate treatment), which achieves ventricular rate regularization without eliminating AF.3 Both strategies—one on rhythm control, the other on rate control—seek to improve hemodynamic function, albeit through different physiological mechanisms. Patient-centered, symptom-directed decisions on rate control and regularization are part of the holistic or integrated care management approach to AF,4 which is advocated in clinical guidelines globally and patient care pathways.5,6 Catheter ablation aims to eliminate AF and restore sinus rhythm, thereby recovering atrial mechanical function and physiological ventricular activation. Randomized trials have demonstrated improvements in ventricular function, symptoms, and clinical outcomes in selected populations with persistent AF and HF.2,7 However, its effectiveness is strongly influenced by the underlying atrial substrate. In persistent AF, particularly in the presence of advanced atrial remodeling and structural heart disease, durable maintenance of sinus rhythm remains challenging, with high rates of arrhythmia recurrence and redo procedures. Notably, a meta-analysis of studies incorporating mandatory remapping procedures demonstrated that, in persistent AF, durable PVI was not associated with a lower risk of AF recurrence, underscoring the dominant role of extrapulmonary vein mechanisms in sustaining the arrhythmia.8 These observations highlight the importance of alternative strategies that do not rely on rhythm restoration, but instead target the hemodynamic consequences of AF. In contrast, pace-and-ablate treatment provides definitive ventricular rate control and, importantly, eliminates the adverse hemodynamic effects of ventricular irregularity.3 In a controlled hemodynamic study, irregular ventricular pacing reduced cardiac output by approximately 12% within minutes compared with regular pacing at identical heart rates, demonstrating that rhythm irregularity itself impairs cardiac function independent of rate.9 Right ventricular apical pacing induces left ventricular dyssynchrony and may promote pacing-induced cardiomyopathy,10 whereas biventricular pacing in patients with a narrow baseline QRS interval may have detrimental effects on prognosis.11 Conduction system pacing (CSP), including His bundle pacing and left bundle branch area pacing, overcomes these limitations by preserving native ventricular activation, thereby strengthening the interest and rationale of the physiological pace-and-ablate strategy.3,7 In this issue of JACC: Asia, Wu et al12 report a prospective observational study comparing CSP combined with AVNA and PVI in patients with persistent AF and markedly enlarged left atria (>50 mm). Patients undergoing AVNA were significantly older, had more advanced structural heart disease at baseline, including lower left ventricular ejection fraction, larger cardiac chambers, and higher natriuretic peptide levels, consistent with more severe HF, and a higher risk profile.2,13 Although propensity score matching improved overall balance between groups, B-type natriuretic peptide levels remained significantly higher in the pace-and-ablate cohort, confirming a greater burden of hemodynamic stress and HF.13 Despite this, over a mean follow-up of approximately 40 months, the incidence of HF hospitalization and cardiac death was similar between both groups (14.9% vs 16.1%), with comparable improvements in ventricular function and functional status. These findings are notable given the presumed higher baseline risk profile in the pace-and-ablate group. A network meta-analysis provides important context for findings by Wu et al,12 demonstrating that pace-and-ablate treatment was associated with a significant reduction in HF hospitalization and cardiovascular events compared with medical therapy and PVI, despite not restoring sinus rhythm.14 In this network meta-analysis, catheter ablation, however, also demonstrates a favorable impact on cardiovascular events and remains the most effective strategy for maintaining sinus rhythm. The emergence of CSP has refined the pace-and-ablate strategy by preserving physiological ventricular activation and likely further improving ventricular and atrial filling pressures.3 These hemodynamic improvements may also favor reverse atrial remodeling. Indeed, spontaneous restoration of sinus rhythm has been observed in a subset of patients after CSP combined with atrioventricular node ablation, suggesting that improving ventricular hemodynamics may indirectly modify the atrial substrate.15 These observations challenge the traditional perception of pace-and-ablate as a strategy of last resort. This view may, in part, reflect anchoring to historical outcomes and contribute to the underuse of an effective therapy.16 In this context, the study by Wu et al12 represents an important milestone toward broader consideration of this strategy in appropriately selected patients. These considerations highlight the importance of patient selection. Catheter ablation is likely to provide the greatest benefit in patients with less advanced atrial disease and a high likelihood of maintaining sinus rhythm, particularly in younger individuals, where avoiding lifelong device dependency is of utmost importance. Conversely, in elderly patients with advanced atrial remodeling, persistent AF, and established HF, strategies that reliably restore ventricular regularity and physiological activation may offer more consistent hemodynamic and clinical benefit.7 However, the long-term implications of iatrogenic pacemaker dependency should not be overlooked. Device-related complications, including infection, lead dysfunction, and the cumulative burden of lifelong cardiac implantable electronic device therapy, remain important considerations. The present study was not designed or powered to assess these long-term risks, and its follow-up duration remains insufficient to evaluate the consequences of chronic device dependency fully. Its most relevant limitation is its nonrandomized nature; therefore, residual confounding cannot be excluded despite propensity matching. Definitive randomized evidence comparing CSP combined with AVNA and PVI in patients with persistent AF and HF is now critically needed. The ongoing ABACUS (Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure; NCT06207383) trial7 will directly compare these strategies. By evaluating clinical outcomes, patient-reported outcomes, experience measures, and cost-effectiveness, this trial will provide essential insights into optimal patient selection and treatment strategy. In conclusion, Wu et al12 provide the first direct comparative observational evidence that CSP combined with AVNA may achieve outcomes comparable with PVI in persistent AF and HF, despite a higher baseline risk profile. These findings support CSP combined with AVNA as an effective option in selected patients. Evidence from randomized trials, including the ongoing ABACUS trial, will be essential to define its role relative to rhythm control. Funding Support and Author Disclosures Dr Kozhuharov has received research grants from the Swiss National Science Foundation (P400PM-194477 and P5R5PM_210856), Gottfried und Julia Bangerter-Rhyner-Stiftung (2020 and 2025), Freiwillige Akademische Gesellschaft, L. & Th. La Roche Stiftung, the European Society of Cardiology, and the European Union/Swiss Secretary for Education, Research and Innovation. Prof Burri has received honoraria from Abbott, Biotronik, Medtronic, and Microport, paid to the institution. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References